Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

Tetsuhiro Tsuruma1 email, Yuji Iwayama1 email, Tosei Ohmura1 email, Tadashi Katsuramaki1 email, Fumitake Hata1 email, Tomohisa Furuhata1 email, Koji Yamaguchi1 email, Yasutoshi Kimura1 email, Toshihiko Torigoe2 email, Nobuhiko Toyota1 email, Atsuhito Yagihashi3 email, Yoshihiko Hirohashi2 email, Hiroko Asanuma2 email, Kumiko Shimozawa4 email, Minoru Okazaki5 email, Yasuhiro Mizushima6 email, Naohiro Nomura7 email, Noriyuki Sato2 email and Koichi Hirata1 email

1Dept. of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

2Dept. of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

3Dept. of Laboratory Diagnosis, Sapporo Medical University School of Medicine, Sapporo, Japan

4Japan Science and Technology Corporation Innovation Plaza Hokkaido, Sapporo, Japan

5Dept. of Surgery, Sapporo Nyusen Geka Clinic, Sapporo, Japan

6Dept. of Surgery, Ashibetsu Municipal Hospital, Ashibetsu, Japan

7Dept. of Medicine, Kitahiroshima Hospital, Kitahiroshima, Japan

author email corresponding author email

Journal of Translational Medicine 2008, 6:24doi:10.1186/1479-5876-6-24

Published: 10 May 2008

Additional files

Additional file 1:

Table 1: Profiles of patients enrolled in the first protocol with survivin-2B peptide alone. The data showed profiles of patients enrolled in the first protocol with survivin-2B peptide alone.

Format: PDF Size: 5KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 2:

Table 2: Profiles of patients enrolled in the second protocol with survivin-2B peptide mixed IFA. The data showed profiles of patients enrolled in the second protocol with survivin-2B peptide mixed IFA.

Format: PDF Size: 4KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 3:

Table 3: Outcome in the first protocol with survivin-2B peptide alone. This data showed the clinical and immunological evaluation in the first protocol.

Format: PDF Size: 84KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 4:

Table 4: Outcome in the second protocol with survivin-2B peptide mixed IFA. This data showed the clinical and immunological evaluation in the second protocol.

Format: PDF Size: 6KB Download file

This file can be viewed with: Adobe Acrobat Reader

© 1999-2008 BioMed Central Ltd unless otherwise stated < info@biomedcentral.com >   Terms and conditions